ROCKVILLE, Md., and BEIJING, June 2, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that Dr. Wei-Wu He, Chairman & CEO will present an overview of the company and provide a business update at the Jefferies 2020 Healthcare Conference on Thursday, June 4, 2020, at 4:00 p.m. ET. The conference will be held in a virtual meeting format.
BPI Labs Llc Generic Melphalan Hydrochloride Receives Approval In US
Actavis ’s Generic Melphalan Hydrochloride Receives Approval In US
Ingenus Pharms`s Generic Melphalan Hydrochloride Receives Approval in US
NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced it has completed patient enrollment in its FOCUS registration trial intended to confirm the potential of its investigational combination treatment for patients with unresectable hepatic-dominant metastatic ocular melanoma (mOM). A total of 80 patients have been enrolled in the trial.
Gland Pharma`s Generic Melphalan Hydrochloride Receives Approval in US
CASI Pharmaceuticals Announces Exclusive Distribution Partner For Melphalan Hydrochloride For Injection (EVOMELA®) In China
WuXi AppTec (SHA: 603259), China's largest CRO/CMO, completed a $1 billion IPO on the Hong Kong markets, pricing the offering in the middle of the expected range. In May, WuXi became a public company by completing a $328 million IPO in Shanghai. Since the offering, the company's shares have nearly quadrupled.
Dr.Reddy's Laboratories today said it has launched Melphalan Hydrochloride for Injection, a therapeutic equivalent generic version of Alkeran (melphalan hydrochloride) for Injection, in the United States market.
Fresenius Kabi USA Generic Melphalan Hydrochloride Receives Approval In US